OniX Hub & OniX AI - Transforming Data into Decisions

Unlock the Power of Intelligence: OniX Hub and OniX AI at a Glance

1.Global Data Aggregation:

- Access a comprehensive repository of global research data, providing a panoramic view of the therapeutic landscape.
- Tailored news, publications, clinical trials, projects, and assets streamline your focus, delivering information pertinent to your company's unique interests.

2.Democratizing Intelligence:

- Break down traditional barriers to intelligence gathering; OniX Hub ensures that data-driven insights are accessible to academia, startups, and biotech at friendly pricing.
- OniX AI amplifies this accessibility, transforming vast amounts of data into actionable steps that support R&D activities across diverse sectors.

3.Proactive Derisking with OniX AI:

- Revolutionize your R&D strategy with OniX AI's advanced capabilities, providing a dynamic understanding of preclinical and clinical landscapes.
- Concrete, actionable steps derived from OniX AI analysis enable companies to proactively derisk decisions and navigate the intricate landscape of therapeutic development.

Unlocking Intelligence for Tomorrow's Therapeutics: The Power of OniX Hub and OniX AI

In the dynamic landscape of academia, startups, biotech, and industry, staying ahead in the race to develop therapeutics requires not only access to data but also real-time intelligence and competitive insights. OniX Hub, in conjunction with OniX AI, is reshaping the game by aggregating global research data, providing a one-stop knowledge portal tailored to the unique needs of each company.

The Need for Up-to-Date Intelligence

In the pursuit of therapeutics, companies must proactively de-risk ongoing R&D and future endeavors in regulatory affairs, intellectual property, manufacturing, patient engagement, and market intelligence. OniX Hub addresses this need by offering easy access to research projects, assets, products, and customized news related to therapeutics, targets, and technologies of interest.

OniX AI Elevates Capabilities

Now, with the upgraded capabilities of OniX AI, the OniX Hub becomes more than just a repository. It transforms into a tool that easily interprets preclinical and clinical landscapes, informing company strategy, R&D decisions, business development initiatives, and vision. Additionally, the robust search functionality enables the discovery of new and innovative ideas, facilitating a proactive approach to knowledge acquisition.

A One-Stop Knowledge Portal

While academia, startups, and biotech traditionally rely on ad-hoc methods such as conferences, journals, and networks, industry maintains infrastructure for rigorous intelligence systems. OniX Hub bridges this gap, providing a global knowledge portal that democratizes intelligence gathering. OniX AI takes it a step further by analyzing vast data and presenting actionable steps at an affordable price for academia, startups, and biotech.

Contact us at martin@onixhub.com | www.onixhub.com

4.Strategic Partnerships:

- OniX Hub acts as a catalyst for connections, providing access to a network of emerging companies, global pharma partners, Key Opinion Leaders (KOLs), and other collaborators.
- Strengthen your ecosystem and explore potential partnerships that fuel innovation and accelerate your journey towards therapeutic breakthroughs.

5.Tailored to Your Company:

- OniX Hub is not a one-size-fits-all solution; it's a personalized knowledge portal crafted to meet the specific needs of each company.
- Customize your data intake, streamline decision-making, and enhance your competitive edge with OniX Hub's adaptable framework.

6.Friendly Pricing for All:

- OniX AI is committed to democratizing advanced intelligence at a price point that supports academia, startups, and biotech.
- Elevate your R&D capabilities without breaking the bank – embrace the power of OniX Hub and OniX AI today.

Transform your data into decisions. Unleash the potential of OniX Hub and OniX AI for a future driven by innovation.

Contact us to learn more and request a demonstration of this unmatched industry resource.
martin@onixhub.com

Democratizing Intelligence Gathering

OniX's global outreach ensures a robust platform for knowledge transfer, supporting R&D activities across the board. Our solution democratizes intelligence gathering, making it accessible to all, while OniX AI ensures it's actionable and derisks critical decisions.

Expand Your Knowledge Today

Take the next step in advancing your R&D activities. Reach out to us to explore how OniX Hub and OniX AI can be tailored to meet your specific needs. Attached are draft examples of preclinical and clinical landscape analyses for a glimpse into the transformative power of our tools.

We look forward to empowering your journey toward therapeutic breakthroughs.



Please see Preclinical and Clinical Landscape Analysis Report

OniX AI for knowledge discovery from scientific text data, aiming to accelerate scientific progress and potentially leading to breakthroughs in research.

Network graphs and Cluster Analysis	
Tauopathies	DMD
	

Tauopathies Preclinical Landscape - DRAFT

Organization Name	Contact PI / Project Leader	Project Title	OniX Summary
UNIVERSITY OF IOWA	LIU, GUANGHAO	Tau-Fyn interaction in normal and diseased states of the brain	This project aims to understand the role of the interaction between Fyn and Tau protein in both healthy and diseased brains, specifically in Frontotemporal dementia linked to chromosome 17 (FTDP-17). The project investigates this interaction by creating mice lacking both Fyn and Tau proteins, and then introducing a specific FTDP-17 causing mutation in Tau. By comparing these mice to various control groups, the researchers hope to identify if and how Fyn depletion affects the progression of FTDP-17. This research may lead to establishing Fyn as a crucial target for developing new drugs to slow or prevent neurodegeneration in tauopathies like FTDP-17.
Columbia University Irving Medical Center	Joseph B. Rayman	Development of Small Molecule Inhibitors of Tau Oligomerization	This research focuses on developing drugs targeting oligomeric tau, a specific form of tau protein linked to Progressive Supranuclear Palsy (PSP) and other tauopathies. This project specifically targets oligomeric tau, a potentially harmful form of tau believed to contribute to neurodegeneration in these diseases. New drug development opportunity: The project aims to identify new compounds that prevent tau oligomerization, potentially leading to novel therapies for PSP and other tauopathies. This approach targets a specific form of tau and could provide a new avenue for treating these currently untreatable diseases.
J. DAVID GLADSTONE INSTITUTES	MUCKE, LENNART	Mouse Models with Regulatable Cell Type-specific Expression of Anti-Tau shRNAs	This research investigates the potential of reducing Tau protein as a treatment for Alzheimer's disease and other tauopathies. The project uses mice to explore the safety and effectiveness of Tau reduction in preventing cognitive decline and seizures linked to the amyloid-beta protein, another hallmark of Alzheimer's disease. The project's design holds promise for new drug development opportunities targeting Tau reduction. If proven safe and effective, this approach could lead to novel therapies for Alzheimer's disease and other related neurological conditions.



DMD disease Preclinical Landscape - DRAFT

Organization Name	Project Leader	Project Title	OniX Summary
UT SOUTHWESTERN MEDICAL CENTER	OLSON, ERIC N	Project 1	This project focuses on using CRISPR/Cas9 gene editing to correct the genetic mutation in Duchenne muscular dystrophy (DMD). DMD is a muscle wasting disease caused by mutations in the dystrophin gene. This project has successfully corrected the dystrophin gene mutation in animal models and aims to further optimize the approach for potential future clinical trials in humans. While challenges remain, this project holds promise for developing a new therapeutic approach to permanently cure DMD.
CHILDREN'S RESEARCH INSTITUTE	HEIER, CHRISTOPHER RYAN	Mechanisms of corticosteroids in dystrophic cardiomyopathy	This research focuses on developing a safer and more targeted corticosteroid therapy for Duchenne muscular dystrophy (DMD). DMD is a muscle wasting disease that also affects the heart. The project investigates how current corticosteroids work and aims to develop new ones with fewer side effects. This project is directly related to DMD as it seeks to improve the treatment of heart problems, a major cause of death in DMD patients. If successful, this project could lead to new drug development opportunities by providing safer and more effective corticosteroid treatments for DMD and potentially other diseases with heart failure or chronic inflammation.
JOHNS HOPKINS UNIVERSITY	LIN, BRIAN LEEI	TRPC6 inhibition therapy to rescue cardiac muscle dysfunction in muscular dystrophy	This research focuses on a new drug called BI 749327 that targets a protein called TRPC6, which is overactive in Duchenne muscular dystrophy (DMD). DMD is a muscle wasting disease that also affects the heart. The project aims to test how effective BI 749327 is in treating DMD and understand how it works. This project is directly related to DMD as it investigates a new potential treatment for the disease. If successful, this project could lead to new drug development opportunities by providing a new treatment option for DMD, specifically targeting the overactive TRPC6 protein.
RUTGERS BIOMEDICAL AND HEALTH SCIENCES	NOUET, JULIE	Role of Connexin43 in the heart and skeletal muscle in a model for Duchenne muscular dystrophy symptomatic carriers	This research focuses on developing new treatments for Duchenne Muscular Dystrophy (DMD) female carriers, a previously understudied group. DMD is a genetic disease affecting muscle function, and this project investigates a protein called Connexin-43 (Cx43) that plays a role in the development of heart and skeletal muscle problems in DMD female carriers. This project is directly related to DMD as it explores new therapeutic options for a specific group within the disease population (symptomatic female carriers). If successful, this research could lead to new drug development opportunities by identifying Cx43 as a potential target for treating DMD female carriers. The project explores the effectiveness of both reducing Cx43 levels and modifying its form to prevent heart and muscle problems.
MYOGENE BIO, LLC	YOUNG, COURTNEY	Comparison of single versus dual vector delivery of AAV-SPY-DYS45-55 for	This research by MyoGene Bio focuses on comparing two delivery methods for a gene editing therapy for Duchenne muscular dystrophy (DMD). DMD is a muscle wasting disease caused by mutations in the dystrophin gene. This project is directly related to DMD as it investigates different ways to deliver a potential new treatment using CRISPR gene editing to correct the mutated gene. If successful, this research could



DRAFT CT Landscape Analysis - PHASE 1: Atopic Dermatitis

ID Number	Interventions	Route	MOA	Sponsor
NCT05945810	DRUG: TLL-018 extended-release tablet|DRUG: TLL-018 immediate-release tablet	ER tablet	highly selective dual TYK2/JAK1 inhibitor for inflammatory and autoimmune diseases unparalleled selectivity with respect to JAK2, JAK3 and other kinases.	Hangzhou Highlightll Pharmaceutical Co., Ltd
NCT05590338	DRUG: GSK1070806 DRUG: Placebo	IV	GSK-1070806 is a humanized IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18)	GlaxoSmithKline
NCT05803902	DRUG: Experimental drug 9MW1911|DRUG: Placebo	IV	Binding specifically to the target ST2, it blocks the activation of ST2-mediated signaling pathway induced by cytokine IL-33, hence inhibiting the	Mabwell (Shanghai) Bioscience Co., Ltd.
NCT03250663	BEHAVIORAL: Online Treatment response|DRUG: EUCRISA	topical	Targets PDE4 (phosphodiesterase 4)	Wake Forest University Health Sciences
NCT00798226	DIETARY_SUPPLEMENT: n-3 fatty acid|DIETARY_SUPPLEMENT: olive oil	tablet	Suppress Th2-associated cytokine gene expressions and GATA transcription factors in mast cells	Copenhagen Studies on Asthma in Childhood
NCT03646604	DRUG: Upadacitinib (ABT-494)	ER tablet	Inhibiting intracellular cytoplasmic enzymes Janus kinases (JAK)	AbbVie